You are here: Industry Insights > Bispecific Antibody

News List

Development Progress of Bispecific Antibodies in China Yefenghong/PharmaSources
November 07, 2023
Approved Bispecific Antibody Products Worldwide, New progress in the field of bispecific antibodies.
The Accepted Marketing Application of Roche's Glofitamab in China Yefenghong/PharmaSources
March 01, 2023
Recently, the marketing application of Roche's Glofitamab has been accepted by NMPA in China.
The Boosting Bispecific Antibody Therapeutics Market: Market Size Exceeded USD3.5 Billion by 2021 PharmaSources/Yi
March 30, 2022
So far this year, there has been good news on the bispecific antibody therapeutics market.
Akeso, Inc. Has Made Positive Progress on Bispecific Antibody with Pipelines Enriched PharmaSources/Chuxin
September 09, 2021
On August 24, Akeso, Inc. announced that the registered Phase II clinical research of its independently-developed global first new tumor immunotherapy drug...
Alphamab Oncology Announced IND Approval of PD-L1/OX40 Bispecific Antibody KN052 prnasia
February 14, 2022
Alphamab Oncology (stock code: 9966.HK) announced, that the company received the IND approval from the National Medical Products Administration (NMPA) for the company's innovative bispecific antibody KN052...
ImmuneOncia, WuXi Biologics partner for bispecific antibody development Pharmaceutical-Technology
December 30, 2021
ImmuneOncia Therapeutics has signed a Memorandum of Understanding (MoU) with WuXi Biologics to develop and manufacture bispecific antibody, IOH-001.
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China prnasia
December 17, 2021
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE)..
Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) prnasia
December 07, 2021
Today, Akeso, Inc. (9926.HK) announced that the company will support an investigator-initiated study (IIS) to evaluate the efficacy and safety of Akeso's novel, first-in-class anti-PD-1/CTLA-4 bispecific antibody, cadonilimab...
Henlius Novel Anti PD-L1/TIGIT Bispecific Antibody Received Clinical Trial Approval in Australia prnasia
November 26, 2021
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the filing of a clinical trial for HLX301, a Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients with locally advanced...
IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE prnasia
October 21, 2021
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced IND application for a phase III clinical study of recombinant humanized anti-HER2 bispecific antibody KN026...

Previous page 1 2 3 Next page